TOKYO, Feb. 2, 2024 /PRNewswire/ — Minato City in Tokyo has issued the winter and latest edition of its tour brochure, “The Best of Minato City,” for overnight visitors. The brochure is designed to encourage visitors to Minato City from Japan and abroad to enjoy reading about the charms…
Month: February 2024
– DXC Technology es nombrada empresa de alto desempeño en el estudio europeo de abastecimiento de TI 2023/2024 de Whitelane Research El proveedor global de servicios de tecnología, DXC Technology, obtuvo una puntuación alta en el ranking general de satisfacción del cliente. ASHBURN, Va.,…
Der globale Technologiedienstleister DXC Technology hat in der Gesamtwertung der Kundenzufriedenheit gut abgeschnitten ASHBURN, Va., 2. Februar 2024 /PRNewswire/ —- DXC Technology (NYSE: DXC), ein führender globaler Fortune-500-Technologiedienstleister, hat sich eine Top-Fünf-Position…
ROUSSET, France, Feb. 2, 2024 /PRNewswire/ — THERYQ, a French company specializing in the development of FLASH radiotherapy systems, and Gustave Roussy, the leading French and European center for cancer research, ranked 4th worldwide, are selected as part of the “i-Démo” / France 2030…
NEW YORK, Feb. 2, 2024 /PRNewswire/ — The Debt Collection Software Market is estimated to grow at a CAGR of 8.92% between 2023 and 2028. The market size is forecast to increase by USD 2.31 billion. APAC is estimated to contribute 31% to the growth of the global market during the forecast…
NEW YORK, Feb. 2, 2024 /PRNewswire/ — The Debt Collection Software Market is estimated to grow at a CAGR of 8.92% between 2023 and 2028. The market size is forecast to increase by USD 2.31 billion. APAC is estimated to contribute 31% to the growth of the global market during the forecast…
Strong revenue generation in Q4 2023 including SEK 43m in Idefirix® product sales supported by growth in new markets such as U.K., Germany, and Spain Encouraging results from first-in-human trial of HNSA-5487 Initiation of phase 1b trial of imlifidase as pre-treatment to Sarepta’s…
Strong revenue generation in Q4 2023 including SEK 43m in Idefirix® product sales supported by growth in new markets such as U.K., Germany, and Spain Encouraging results from first-in-human trial of HNSA-5487 Initiation of phase 1b trial of imlifidase as pre-treatment to Sarepta’s…
STOCKHOLM, Feb. 2, 2024 /PRNewswire/ — Improved operating margin and strong cash flow for the year Fourth quarter 2023 Net sales decreased by 17% to SEK 8,605m (10,353). Changes in exchange rates impacted with -1%. Planned exits of low-margin petrol-powered business impacted with -2%….
STOCKHOLM, Feb. 2, 2024 /PRNewswire/ — Improved operating margin and strong cash flow for the year Fourth quarter 2023 Net sales decreased by 17% to SEK 8,605m (10,353). Changes in exchange rates impacted with -1%. Planned exits of low-margin petrol-powered business impacted with -2%….